^
    1d
    Homologous recombination (HR) and DNA damage repair (DDR) somatic alterations in metastatic colorectal cancer (mCRC): results from the comprehensive genomic profiling (CGP) trial FPG500 (AIOM 2024)
    Background : Treatment (tx) of MSS/MMRp mCRC relies mainly on oxaliplatin (oxa)- or irinotecan-based doublet chemotherapy regimens, with no biomarker reported so far, allowing the selection of one tx over the other. HR-DDRa is associated with MSI-H or TMB-H. Pts with MSS HR-DDRa tumors benefit from oxa-based first line treatment. Longer FU, allowing mature OS data, and wider cohorts are warranted.
    Tumor mutational burden • BRCA Biomarker • MSi-H Biomarker • Metastases
    |
    TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • BAP1 (BRCA1 Associated Protein 1) • PALB2 (Partner and localizer of BRCA2) • ATRX (ATRX Chromatin Remodeler) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD50 (RAD50 Double Strand Break Repair Protein) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • MRE11A (MRE11 homolog, double strand break repair nuclease) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • FANCL (FA Complementation Group L) • FANCD2 (FA Complementation Group D2) • FANCE (FA Complementation Group E) • FANCC (FA Complementation Group C)
    |
    TMB-H • MSI-H/dMMR
    |
    TruSight Oncology 500 Assay
    |
    oxaliplatin • irinotecan
    2d
    Long non-coding RNA AC105118.1 affects glycolysis to facilitate oxaliplatin resistance in colorectal cancer cells by modulating the miR-378a-3p/KIF26B axis. (PubMed, Int J Biochem Cell Biol)
    AC105118.1 facilitates glycolysis and increases CRC cells' resistance to oxaliplatin by targeting the miR-378a-3p/KIF26B axis. The present work shed new insights into the function and mechanism of AC105118.1 in molecular function and suggested that the AC105118.1/miR-378a-3p/KIF26B axis is a promising target for intervening CRC oxaliplatin resistance.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • MIR378A (MicroRNA 378a) • SLC2A1 (Solute Carrier Family 2 Member 1) • KIF26B (Kinesin Family Member 26B)
    |
    oxaliplatin
    3d
    Identification of basement membrane-related prognostic model associated with the immune microenvironment and synthetic therapy response in pancreatic cancer: integrated bioinformatics analysis and clinical validation. (PubMed, J Cancer)
    PCs with a low BM-related score had a better outcome and were more likely to benefit from oxaliplatin, irinotecan, and KRAS(G12C) inhibitor-12, and immunotherapy. Molecular docking indicated that epigallocatechin gallate had a strong binding activity with DSG3, MET, and PLAU and may be used as a potential therapeutic agent for PC. In conclusion, this study developed a BM-related model associated with PC prognosis, immune infiltration, and treatment, which provided new insights into PC stratification and drug intervention.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • PLAU (Plasminogen Activator)
    |
    oxaliplatin • irinotecan
    3d
    Huaier promotes sensitivity of colorectal cancer to oxaliplatin by inhibiting METTL3 to regulate the Wnt/β‑catenin signaling pathway. (PubMed, Oncol Rep)
    Silencing METTL3 promoted apoptosis of CRC cells and increased their sensitivity to OXA by inhibiting the Wnt/β‑catenin signaling pathway. Huaier downregulated the expression of METTL3, thereby promoting apoptosis of drug‑resistant CRC cells and increasing their sensitivity to OXA by inhibiting the Wnt/β‑catenin signaling pathway.
    Journal
    |
    METTL3 (Methyltransferase Like 3)
    |
    oxaliplatin
    3d
    Capecitabine enhances sensitivity to oxaliplatin in advanced gastric cancer and the effects on patients' FOXP1 and GGT levels. (PubMed, Heliyon)
    Gastric cancer patients with age <60 years, TNM stage of Ⅰ ∼ Ⅱ, lymph node metastasis N0 ∼ N1, high expression of FOXP1, GGT <387.2, and combined with drug chemotherapy had higher survival rate. Capecitabine effectively enhanced the sensitivity of intermediate and advanced gastric cancer to oxaliplatin, improved the therapeutic effect, reduced the proportion of patients with low FOXP1 expression rate and serum GGT level, decreased the recurrence rate and ameliorated the prognosis of patients.
    Journal • Metastases
    |
    FOXP1 (Forkhead Box P1)
    |
    capecitabine • oxaliplatin
    3d
    Establishment and Clinical Significance of the Patient-Derived Xenograft Model of Colorectal Cancer. (PubMed, Cureus)
    The CRC-PDX model established in this study can maintain the biological characteristics of primary tumors and can be used as a reference model for the individualized treatment of CRC patients. The degree of malignancy of the primary tumor is the primary factor affecting the tumorigenesis rate of the PDX model.
    Preclinical • Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    5-fluorouracil • oxaliplatin
    3d
    Patients with T4N0 and T1‑3N1 colon cancer and a high preoperative carcinoembryonic antigen level benefit from adjuvant chemotherapy with oxaliplatin for 6 months. (PubMed, Oncol Lett)
    However, the prognosis of patients in the low-risk group with high CEA levels improved with a 6-month adjuvant treatment with oxaliplatin to a similar level to that of all patients with low CEA levels in the low-risk group. In conclusion, the present study suggested that the duration of adjuvant chemotherapy with oxaliplatin should not be shortened in patients with high preoperative CEA levels, even in the low-risk group.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    oxaliplatin
    4d
    Compound 4a induces paraptosis in liver cancer through endoplasmic reticulum stress mediated by the calreticulin protein. (PubMed, Br J Pharmacol)
    Compound 4a represents a potentially safe and effective agent for the treatment of liver cancer. The characteristics of Compound 4a-triggered paraptosis was clarified and a unique function of CRT in paraptosis was revealed.
    Journal
    |
    CALR (Calreticulin)
    |
    oxaliplatin
    5d
    FIRM: A Pospective, Single-arm, Multicenter Clinical Trial Evaluating Preoperative Neoadjuvant MFOLFOX6 Chemotherapy in Combination with PD1 Monoclonal Antibody in MSS/pMMR Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
    New trial
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium
    6d
    Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=28, Recruiting, Yale University | Trial completion date: Feb 2025 --> Feb 2027 | Trial primary completion date: Aug 2024 --> Aug 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    oxaliplatin • irinotecan
    14d
    RILUZOX-01: Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy. (clinicaltrials.gov)
    P2, N=80, Suspended, UNICANCER | Trial completion date: Oct 2024 --> Mar 2025 | Active, not recruiting --> Suspended | Trial primary completion date: Sep 2024 --> Mar 2025
    Trial completion date • Trial suspension • Trial primary completion date
    |
    oxaliplatin • riluzole
    15d
    Integrated bulk and single-cell profiling characterize sphingolipid metabolism in pancreatic cancer. (PubMed, BMC Cancer)
    This study revealed the important significance of SM in PC and identified SM-associated molecular subtypes and prognostic model, which provided novel perspectives on the stratification, prognostic prediction, and precision treatment of PC patients.
    Journal
    |
    CD8 (cluster of differentiation 8) • DKK1 (dickkopf WNT signaling pathway inhibitor 1) • ANKRD22 (Ankyrin Repeat Domain 22) • ANLN (Anillin Actin Binding Protein)
    |
    gemcitabine • paclitaxel • oxaliplatin
    15d
    Mitotic Arrest Deficient 2 Like 1 Contributes to Colorectal Cancer Cell Migration, Invasion, and Oxaliplatin Resistance Through the Wnt/β-Catenin Pathway. (PubMed, Chem Biol Drug Des)
    The progression capacities of CRC cells were assessed using transwell and wound healing assays, and the resistance to cisplatin in oxaliplatin-resistant CRC cells was assessed using CCK-8 assay and flow cytometry. After the knockdown of MAD2L1, the inhibition of the Wnt/β-catenin pathway exhibited a synergistic effect, effectively suppressing malignant progression and reversing oxaliplatin resistance in CRC cells. So, knockdown of MAD2L1 suppressed cell malignant progression, equally sensitized resistant CRC cells to oxaliplatin, potentially by blocking the activation of the Wnt/β-catenin pathway.
    Journal
    |
    ABCG2 (ATP Binding Cassette Subfamily G Member 2) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1)
    |
    cisplatin • oxaliplatin
    19d
    Enhancing sensitivity to oxaliplatin in tongue squamous cell carcinoma: mechanistic insights and therapeutic potential of DHA combination therapy. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    This leads to reduced expression of anti-apoptotic genes and facilitates programmed cell death in CAL-27 cells. The findings underscore the potential of DHA and Oxa as a potent therapeutic strategy for tongue squamous cell carcinoma, opening avenues for clinical application and further exploration into its mechanistic pathways.
    Journal • Combination therapy
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • CASP3 (Caspase 3) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)
    |
    oxaliplatin
    19d
    FBW7-Mediated Degradation of CHD3 Suppresses Hepatocellular Carcinoma Metastasis and Stemness to Enhance Oxaliplatin Sensitivity. (PubMed, Front Biosci (Landmark Ed))
    FBW7 overexpression suppresses HCC cell metastasis, stemness and oxaliplatin resistance via targeting CHD3 for ubiquitylation and degradation.
    Journal
    |
    FBXW7 (F-Box And WD Repeat Domain Containing 7)
    |
    FBXW7 overexpression
    |
    oxaliplatin
    19d
    METTL3 confers oxaliplatin resistance through the activation of G6PD-enhanced pentose phosphate pathway in hepatocellular carcinoma. (PubMed, Cell Death Differ)
    Notably, treatment with the specific METTL3 inhibitor, STM2457, significantly improved the efficacy of oxaliplatin. These findings underscore the critical role of the METTL3/TRIM21/G6PD axis in driving oxaliplatin resistance and present a promising strategy to overcome chemoresistance in HCC.
    Journal
    |
    METTL3 (Methyltransferase Like 3) • TRIM21 (Tripartite Motif Containing 21) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2)
    |
    oxaliplatin
    20d
    LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib (clinicaltrials.gov)
    P3, N=545, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    lapatinib • capecitabine • oxaliplatin
    21d
    Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer (clinicaltrials.gov)
    P2, N=77, Completed, University of Washington | Active, not recruiting --> Completed | Trial completion date: Sep 2024 --> Mar 2024
    Trial completion • Trial completion date
    |
    oxaliplatin
    21d
    Ultrasound for the Detection of Oxaliplatin-Induced Peripheral Neuropathy (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, Wake Forest University Health Sciences | Trial completion date: Oct 2024 --> Mar 2025 | Trial primary completion date: Oct 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    oxaliplatin
    21d
    Phase 1 Study of ROR1 Specific CAR T Cells in Advanced Hematopoietic and Epithelial Malignancies. (PubMed, Clin Cancer Res)
    ROR1 CAR T cells were well tolerated in most patients. Antitumor activity was observed in CLL but was limited in TNBC and NSCLC. Immunogenicity of the CAR and lack of sustained tumor infiltration were identified as limitations.
    P1 data • Journal • CAR T-Cell Therapy • Metastases
    |
    ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
    |
    ROR1 expression
    |
    cyclophosphamide • oxaliplatin • fludarabine IV
    21d
    MicroRNA-582-5p inhibits the progression of gastric cancer cells and their resistance to oxaliplatin by suppressing ATG7 expression. (PubMed, Front Oncol)
    Our study confirms that microRNA-582-3p acts as a tumor suppressor in gastric cancer cells, and its role may be mediated through the regulation of ATG7 expression levels. MicroRNA-582-3p may serve as a potential target for gastric cancer treatment and a predictive biomarker.
    Journal
    |
    ATG7 (Autophagy Related 7) • MIR582 (MicroRNA 582)
    |
    oxaliplatin
    23d
    Global Leadership Initiative on Malnutrition Criteria and Immunonutritional Status Predict Chemoadherence and Survival in Stage II/III Gastric Cancer Treated with XELOX Chemotherapy. (PubMed, Nutrients)
    This study highlights the critical role of immunonutritional status, particularly as measured using the GLIM criteria, in maintaining adherence to chemotherapy and improving survival outcomes in patients with gastric cancer. Routine preoperative nutritional assessments using GLIM can help identify high-risk patients, and early nutritional interventions may improve chemotherapy adherence and outcomes. These findings support the integration of nutritional strategies, specifically targeting those identified by the GLIM, into standard care to enhance the efficacy and survival of chemotherapy.
    Retrospective data • Journal • Adherence
    |
    CRP (C-reactive protein)
    |
    capecitabine • oxaliplatin
    26d
    ADORE: Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer (clinicaltrials.gov)
    P2, N=322, Completed, Asan Medical Center | Unknown status --> Completed
    Trial completion • Surgery • Metastases
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium
    26d
    RAPIDO vs LCRT vs Upfront Surgery - a Prospective Cohort Study (clinicaltrials.gov)
    P=N/A, N=57, Active, not recruiting, Sengkang General Hospital | Trial completion date: Jun 2024 --> Dec 2024
    Trial completion date • Surgery
    |
    capecitabine • oxaliplatin
    27d
    The Effect of ZnO Nanoparticles Functionalized with Glutamine and Conjugated with Thiosemicarbazide on Triggering of Apoptosis in the Adenocarcinoma Gastric Cell Line. (PubMed, Adv Biomed Res)
    The toxicity of ZnO NPs, TSC, ZnO@Gln-TSC NPs, and oxaliplatin in AGS cells and ZnO NPs and ZnO@Gln-TSC NPs in HEK293 cells was investigated by MTT assay...The activity of caspase-3 and the expression level of the CASP3 gene were increased by1.83 and 1.6 folds after exposure to ZnO@Gln-TSC NPs, respectively. This study revealed the anti-cancer potential of ZnO@Gln-TSC NPs to be used for gastric cancer treatment after further in vitro and in vivo assays.
    Preclinical • Journal
    |
    CASP3 (Caspase 3)
    |
    oxaliplatin
    1m
    Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients with GI Malignancies (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, University of Vermont Medical Center
    New P2 trial
    |
    capecitabine • oxaliplatin
    1m
    MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=51, Not yet recruiting, Washington University School of Medicine
    New P1 trial • Combination therapy • Metastases
    |
    oxaliplatin • irinotecan • zunsemetinib (ATI-450)
    1m
    HEPATOXALI: Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Blood Levels of HMGB1 (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, University Hospital, Clermont-Ferrand
    New trial
    |
    HMGB1 (High Mobility Group Box 1)
    |
    oxaliplatin
    1m
    EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Therakos, LLC, a Mallinckrodt Company
    New P2 trial • Checkpoint inhibition
    |
    Entyvio (vedolizumab)
    1m
    Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia. (PubMed, Leukemia)
    In vivo combination treatment of leukemic animals with high PDE3A expression significantly reduced leukemia burden and prolonged survival time compared with single-drug and vehicle control treatments. Our findings suggest that combined ANA and IDA treatment is an innovative and promising therapeutic strategy for AML patients with high PDE3A expression.
    Journal
    |
    CASP3 (Caspase 3) • PDE3A (Phosphodiesterase 3A) • GSDME (Gasdermin E)
    |
    PDE3A overexpression
    |
    idarubicin hydrochloride
    1m
    Identification of key lncRNAs associated with oxaliplatin resistance in colorectal cancer cells and isolated exosomes: From In-Silico prediction to In-Vitro validation. (PubMed, PLoS One)
    The high levels of these lncRNAs in exosomes of resistant cells suggest their involvement in intercellular communication and resistance propagation. This positioning makes them promising biomarkers for OXP-resistance in CRC.
    Preclinical • Journal
    |
    MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • NEAT1 (Nuclear Paraspeckle Assembly Transcript 1)
    |
    oxaliplatin
    1m
    Identification of molecular targets and underlying mechanisms of Fuzheng Shengbai Decoction against colon cancer based on network pharmacology. (PubMed, Am J Transl Res)
    This study identified the molecular targets and underlying mechanisms of FZSBD treatment against CC and may provide clues for future research on the treatment of CC with FZSBD.
    Journal
    |
    TP53 (Tumor protein P53) • CCND1 (Cyclin D1) • IL1B (Interleukin 1, beta)
    |
    capecitabine • oxaliplatin
    1m
    Aberrant FAM135B attenuates the efficacy of chemotherapy in colorectal cancer by modulating SRSF1-mediated alternative splicing. (PubMed, Oncogene)
    Oxaliplatin is the frontline chemotherapy drug for the treatment of colorectal cancer (CRC) and its insensitivity is a major limitation on therapeutic efficacy...These findings reveal that the FAM135B-SRSF1 axis-mediated splicing contributes to DNA repair and chemotherapeutic insensitivity in CRC. Targeting FAM135B represents a potential strategy for CRC treatment.
    Journal
    |
    SRPK1 (SRSF Protein Kinase 1)
    |
    oxaliplatin
    1m
    Gastric Cancer Actively Remodels Mechanical Microenvironment to Promote Chemotherapy Resistance via MSCs-Mediated Mitochondrial Transfer. (PubMed, Adv Sci (Weinh))
    However, the mechanism of oxaliplatin (OXA) resistance remains unclear...Meanwhile, inhibiting the mechanical-related RhoA/ROCK1 pathway could alleviate OXA resistance in GC cells. In summary, these results indicate that matrix stiffness could be used as an indicator to identify chemotherapy resistance, and targeting mechanical-related pathway could effectively alleviate OXA resistance and improve therapeutic efficacy.
    Journal
    |
    RHOA (Ras homolog family member A)
    |
    oxaliplatin
    1m
    DNA methylation-driven gene FAM3D promotes colorectal cancer growth via the ATF4-SESN2-mTORC1 pathway. (PubMed, Aging (Albany NY))
    Furthermore, FAM3D resulted in reduced sensitivity of CRC cells to oxaliplatin, cisplatin, and 5-fluorouracil. Our study showed that FAM3D activates the mTORC1 pathway through the ATF4-SESN2 axis and promotes the malignant progression of CRC, which contributes to predict CRC prognosis and guide individualized treatment.
    Journal • Epigenetic controller
    |
    ATF4 (Activating Transcription Factor 4) • SESN2 (Sestrin 2)
    |
    cisplatin • 5-fluorouracil • oxaliplatin
    1m
    Hypoxia-Associated GPNMB+ Macrophages Promote Malignant Progression of Colorectal Cancer and Its Related Risk Signature Are Powerful Predictive Tool for the Treatment of Colorectal Cancer Patients. (PubMed, Environ Toxicol)
    Patients with low HMRS were sensitive to fluorouracil, oxaliplatin (FOLFOX), and anti-PD-1 immunotherapy, while those with high HMRS showed resistance. Additionally, HMRS was identified as an independent prognostic factor in other digestive tract tumors (hepatocellular carcinoma, pancreatic cancer, esophageal cancer, and gastric cancer), indicating potential extrapolation to other tumor types. In conclusion, GPNMB+ Macr promotes the malignant progression of CRC, and HMRS serves as a powerful predictive tool for prognosis, chemotherapy, and immunotherapy in CRC patients, aiding in improving the quality of survival.
    Journal
    |
    GPNMB (Glycoprotein Nmb)
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium
    2ms
    HMGB2-induced calreticulin translocation required for immunogenic cell death and ferroptosis of cancer cells are controlled by the nuclear exporter XPO1. (PubMed, Commun Biol)
    Cisplatin and oxaliplatin cause the secretion of high mobility group box 1 (HMGB1) protein from cancer cells, which is necessary for initiation of immunogenic cell death (ICD). Incubation of cancer cells with cell targeted (CT)-HMGB2 confirmed that HMGB2 is required for the CRT translocation. Furthermore, CT-HMGB2 is three orders of magnitude more potent at inducing CRT translocation than oxaliplatin.
    Journal
    |
    HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin) • HMGB2 (High Mobility Group Box 2)
    |
    cisplatin • oxaliplatin
    2ms
    TCOG T5221: A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=66, Active, not recruiting, National Health Research Institutes, Taiwan | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    gemcitabine • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium
    2ms
    IROCAS: IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting (clinicaltrials.gov)
    P3, N=792, Active, not recruiting, UNICANCER | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial primary completion date
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    5-fluorouracil • oxaliplatin • irinotecan
    2ms
    Successful Cord Blood Transplantation for Myeloid/Natural Killer Precursor Acute Leukemia: A Case Report and Literature Review. (PubMed, Intern Med)
    Although hyper-CVAD therapy was unsuccessful, induction treatment with idarubicin and cytarabine resulted in complete remission (CR). He had been in good health without relapse for over nine months since transplantation. Timely allogeneic hematopoietic stem cell transplantation using an available donor source may be a promising treatment strategy for MNKPL.
    Review • Journal
    |
    CD33 (CD33 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD7 (CD7 Molecule)
    |
    cytarabine • idarubicin hydrochloride
    2ms
    A Benzimidazole-Based N-Heterocyclic Carbene Derivative Exhibits Potent Antiproliferative and Apoptotic Effects against Colorectal Cancer. (PubMed, Medicina (Kaunas))
    Additionally, the addition of IMBZC to conventional chemotherapeutic drugs (i.e., 5-fluorouracil, irinotecan, and oxaliplatin) resulted in an increase in the cytotoxic potential of the drugs. These findings indicate that IMBZC could be a promising chemotherapeutic drug for the treatment of CRC. Further research should be conducted using in vivo models to confirm the anti-CRC activities of IMBZC.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1)
    |
    BCL2 expression • TP53 expression • BAX expression
    |
    5-fluorouracil • oxaliplatin • irinotecan
    2ms
    Changes in AmotL2 Expression in Cells of the Human Enteral Nervous System in Oxaliplatin-Induced Enteric Neuropathy. (PubMed, Biomedicines)
    Our results in human samples show that the total number of neurons and glial cells decreased in OxPt-treated patients, and TNF-α and AmotL2 expression was increased and colocalized in both neurons and glia. AmotL2 differential expression between OxPt-treated and untreated CRC patients shows the involvement of this scaffold protein in the inflammatory component and toxicity by OxPt in the ENS.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    oxaliplatin